推荐产品
质量水平
表单
solid
浓度
18-20% Fe (T)
痕量阴离子
chloride (Cl-): ≤500 mg/kg
痕量阳离子
Ca: ≤100 mg/kg
Cd: ≤50 mg/kg
Co: ≤50 mg/kg
Cu: ≤50 mg/kg
K: ≤500 mg/kg
Na: ≤200 mg/kg
Ni: ≤100 mg/kg
Pb: ≤50 mg/kg
Zn: ≤50 mg/kg
官能团
hydroxyl
SMILES字符串
OC12CC(=O)O[Fe](OC(=O)C1)OC2=O
InChI
1S/C6H8O7.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3
InChI key
NPFOYSMITVOQOS-UHFFFAOYSA-K
正在寻找类似产品? 访问 产品对比指南
应用
柠檬酸三钠一水合物铁 (III) 可用作在制备灌注溶液期间使用的其中一种组合物的铁源。
警示用语：
Warning
危险声明
危险分类
Eye Irrit. 2
储存分类代码
13 - Non Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
A E Gómez-Ayala et al.
Laboratory animals, 32(1), 72-79 (1998-03-03)
The effects of iron deficiency on the absorption of different dietary sources of iron were studied, together with the interactions between iron, calcium, phosphorus, magnesium, copper and zinc in the jejunum-ileum of control and iron-deficient rats. In this study, three
Tatsuya Fukushima et al.
Proceedings of the National Academy of Sciences of the United States of America, 109(42), 16829-16834 (2012-10-03)
Citrate is a common biomolecule that chelates Fe(III). Many bacteria and plants use ferric citrate to fulfill their nutritional requirement for iron. Only the Escherichia coli ferric citrate outer-membrane transport protein FecA has been characterized; little is known about other
Marvin Sinsakul et al.
Nephron. Clinical practice, 121(1-2), c25-c29 (2012-10-19)
A phase II open-label study was conducted in hemodialysis patients evaluating the short-term safety, tolerability, and iron absorption with ferric citrate when used as a phosphate binder. Enrollment occurred in two periods. Period 1 recruited patients taking 6-15 pills/day of
Petra Vukosav et al.
Analytica chimica acta, 745, 85-91 (2012-09-04)
A detailed study of iron (III)-citrate speciation in aqueous solution (θ=25°C, I(c)=0.7 mol L(-1)) was carried out by voltammetric and UV-vis spectrophotometric measurements and the obtained data were used for reconciled characterization of iron (III)-citrate complexes. Four different redox processes
Keitaro Yokoyama et al.
American journal of nephrology, 36(5), 478-487 (2012-11-14)
JTT-751 (ferric citrate hydrate) is a novel oral, iron-based phosphate binder being developed for the treatment of hyperphosphatemia among chronic kidney disease patients who are on dialysis. This study investigated the dose-response and safety of JTT-751 among Japanese hemodialysis patients.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门